Gilead Sciences (NASDAQ: GILD) and Merck (NYSE: MRK) announced that their investigational once-weekly oral HIV treatment combining islatravir and lenacapavir ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA